Create First-in-Class Bispecific & T-Cell Engagers by Reducing Dose Limiting Toxicities Through Antibody Engineering Approaches, Co-Stimulation & Masking Strategies

Bispecifics and T-Cell Engagers are redefining the future of solid tumor treatment. With the landmark approvals of tarlatamab and ivonescimab, the spotlight is firmly on these modalities as powerful solutions for long-standing unmet needs. Despite challenges with dose-limiting toxicities, the field is buzzing with innovation aimed at expanding the therapeutic window through improving next-generation designs.

Innovation is rife within Korea, with companies such as ABL Bio, Novelty Nobility, ABION, and IM Biologics capturing international attention and investment, positioning Korea as a key player in the bispecific and TCE revolution.

To accelerate this momentum, the inaugural World Bispecific & T-Cell Engager Summit South Korea comes as the only event in Asia dedicated to bringing together biopharma professionals focused on the discovery and development of differentiated Bispecifics and T-cell engagers that could become first-in-class therapies. Featuring key international opinion leaders, the agenda will deep dive into co-stimulation techniques, antibody masking, advanced engineering, and bispecific ADCs (bsADCs), spotlighting cutting-edge strategies to overcome toxicity hurdles and helping you build the global collaborations needed to advance best-in-class therapeutics.

As part of the World Targeted Therapeutics Summit South Korea, organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), targeted protein degradation, and induced proximity, which aim to turn South Korea into the next global hub for biopharma innovation in targeted therapeutics. From discovery to manufacturing, you’ll get end-to-end coverage to equip your entire team with the insights needed to innovate and differentiate, ultimately attract interest for global pharma partnerships.